Drug Profile
Research programme: complement protein C3 inhibitor - Incode BioPharmaceutics
Alternative Names: HC3-1496; rC3-1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InCode BioPharmaceutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Complement system protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Paroxysmal-nocturnal-haemoglobinuria in USA
- 23 Jul 2008 Preclinical trials in Paroxysmal nocturnal haemoglobinuria in USA (unspecified route)